Aldeyra announced the advancement of two investigational new drug candidates, ADX-246 and ADX-248, to clinical testing, pending completion of FDA investigational new drug, or IND, requirements. ADX-246 and ADX-248 represent the most recent group of product candidates generated from Aldeyra’s systems-based drug discovery and development engine focused on novel RASP modulators designed to decrease immune responses that lead to disease. Pending completion of the IND requirements, a Phase 1 clinical trial of orally administered ADX-246 for the treatment of systemic immune-mediated diseases, and a Phase 1/2 clinical trial of intravitreally injected ADX-248 for the treatment of geographic atrophy, a sight-threatening retinal disease, are expected to initiate in the second half of 2023 or early 2024.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALDX:
